News for Cell Source, Inc. (CLCS)

Published at

Nov 21, 2024 6:00 PM

by gurufocus.com

neutral

neutral

Cell Source Shares Promising Interim Results From Groundbreaking Veto Cell Clinical Trial

First-of-Its-Kind Success in Mismatched Donor Stem Cell Transplantation: Engraftment Under Mild Immune Suppression with Minimal Graft-versus-Host DiseaseNEW YOR

CLCS

Read more →
Published at

Jul 28, 2022 4:45 PM

by prnewswire.com

negative

negative

Cell Source Announces Resignations of Directors

/PRNewswire/ -- On July 18, 2022, each of Ben Friedman and David Zolty resigned his position as a director of Cell Source, Inc. (the "Company"). Neither Mr....

CLCS

Read more →
Published at

Apr 1, 2021 9:00 PM

by markets.businessinsider.com

neutral

neutral

Darlene Soave Joins Cell Source's Board of Directors

NEW YORK, April 1, 2021 /PRNewswire/ -- Cell Source, Inc. (OTC: CLCS) ('Cell Source' or 'the Company'), is the world leader in Veto Cell based inn...

CLCS

Read more →
Published at

Mar 12, 2021 12:31 PM

by marketscreener.com

mixed

mixed

Veto T-Cell Bone Marrow Transplant Safely Demonstrates Potential Cure for Sickle Cell Anemia in Preclinical Trials

in different mouse models for non-malignant hematological disease and organ transplants announced today that its fully mismatched mouse Veto Cell based BMT protocol has overcome significant challenges...

PPLXF IVSXF CLCS FRNWF

Read more →